| Earnings (Loss) Per Common Share |
17. Earnings (Loss) Per Common Share
Basic earnings (loss) per common share is computed by dividing the net income (loss) allocated to common stockholders by the weighted-average number of shares of Common Stock outstanding during the period. For purposes of calculating diluted earnings (loss) per common share, the denominator includes both the weighted-average number of shares of Common Stock outstanding during the period and the number of common stock equivalents if the inclusion of such common stock equivalents is dilutive. Dilutive common stock equivalents potentially include stock options and warrants using the treasury stock method. The following table summarizes the components of the earnings (loss) per common share calculation (in thousands, except per share amounts):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Nine Months Ended |
|
|
|
March 31, |
|
March 31, |
|
|
|
2023 |
|
2022 |
|
2023 |
|
2022 |
|
Basic and diluted numerator: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss attributable to iBio, Inc. from continuing operations |
|
$ |
(6,279) |
|
$ |
(6,746) |
|
$ |
(24,379) |
|
$ |
(19,125) |
|
Preferred stock dividends – iBio CMO Preferred Tracking Stock |
|
|
— |
|
|
— |
|
|
— |
|
|
(88) |
|
Net loss available to iBio, Inc. stockholders from continuing operations |
|
$ |
(6,279) |
|
$ |
(6,746) |
|
$ |
(24,379) |
|
$ |
(19,213) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss available to iBio, Inc. stockholders from discontinued operations |
|
$ |
(1,015) |
|
$ |
(5,644) |
|
$ |
(34,598) |
|
$ |
(14,124) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss available to iBio, Inc. stockholders - total |
|
$ |
(7,294) |
|
$ |
(12,390) |
|
$ |
(58,977) |
|
$ |
(33,337) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted denominator: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average common shares outstanding |
|
|
13,184 |
|
|
8,719 |
|
|
10,592 |
|
|
8,719 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Per share amount - continuing operations |
|
$ |
(0.47) |
|
$ |
(0.77) |
|
$ |
(2.30) |
|
$ |
(2.20) |
|
Per share amount - discontinued operations |
|
$ |
(0.08) |
|
$ |
(0.65) |
|
$ |
(3.27) |
|
$ |
(1.62) |
|
Per share amount - total |
|
$ |
(0.55) |
|
$ |
(1.42) |
|
$ |
(5.57) |
|
$ |
(3.82) |
|
In Fiscal year 2023 and Fiscal year 2022, the Company incurred net losses which cannot be diluted; therefore, basic and diluted loss per common share is the same. As of March 31, 2023 and 2022, shares issuable which could potentially dilute future earnings were as follows:
|
|
|
|
|
|
|
March 31, |
|
|
2023 |
|
2022 |
|
|
|
(in thousands) |
Stock options |
|
457 |
|
625 |
Restricted stock units |
|
443 |
|
22 |
Warrants |
|
5,948 |
|
52 |
Shares excluded from the calculation of diluted loss per share |
|
6,848 |
|
699 |
|